ACTRN12610000802000尚未招募4 期
Impact of Intensive Medical Treatment in Elderly Patients with Left Ventricle Ejection Fraction >40%, Elevated Left Ventricular Volumes and Abnormal Brain Natriuretic Peptide levels Post Acute Myocardial Infarction on new Heart Failure Hospitalisation (INTENSIVE AMI-HF)
PAH0 个研究点目标入组 200 人开始时间: 2010年9月27日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 60 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adult patients >60 years old 2 weeks post MI (STEMI, NSTEMI)
- •LVEF >40% and
- •LVESVI>30ml/m2 or LVEDVI>75ml/m2 and
- •BNP >100ng/l
排除标准
- •Known heart failure
- •Known LVEF<40%
- •Previous MI (except the primary event)
- •Severe valvular heart disease
- •Severe life span limiting medical disease (cancer, Chronic Obstructive Pulmonary Disease (COPD) with FEV1<1.0 l, renal failure serum Creatinine >200mcmol/l)
- •Systolic Blood Pressure <100mmHg
- •Lack of consent
研究者
相似试验
已完成
不适用
One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically VentilatedElderly CareNCT01679171University Hospital, Angers489
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.EUCTR2016-002272-27-BESaarland University388
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002272-27-ATSaarland University388
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.EUCTR2016-002272-27-PTSaarland University388
进行中（未招募）
1 期
Improvement of Outcome in Elderly Patients or Patients not eligible forhigh-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma infirst Relapse or Progression by adding Nivolumab to Gemcitabine,Oxaliplatin plus Rituximab in case of B-cell lymphoma.EUCTR2016-002272-27-PLSaarland University388